The company recently completed clinical trials for its acute pain formulation, CTL-X, which is the most advanced product in the Veritas pipeline Veritas Pharma works in two directions to put together effective cannabis-based treatments for various medical conditions With the help of R&D partner Cannevert Therapeutics, Veritas is developing solutions for various additional issues like … Continue reading “Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Committed to Developing Most Effective Proprietary Cannabis Strains and Products”
Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), a pharmaceutical and IP development firm, this morning announced that it has entered into a Memorandum of Understanding (“MOU”) with BioCan Technologies Inc. of Calgary, Alberta to collaborate exclusively to conduct additional investigations of cannabis strains being developed by Veritas’ research arm, Cannevert Therapeutics Ltd. (“CTL”). Optimizing … Continue reading “NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Inks MOU with BioCan Technologies”
Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), a pharmaceutical and IP development firm, this morning announced that it has signed an agreement with 906474 ALBERTA LTD (“the vender”), to purchase 100% ownership of Sechelt Organic Marijuana Corp (“SOM”). Under the agreement, Veritas Pharma will purchase all outstanding shares of SOM at a price of … Continue reading “NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Signs Agreement to Acquire Sechelt Organic Marijuana Corp.”
Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning issued an official corporate update on its achievements, related scientific activities and growth strategies for the first quarter of fiscal 2018. Highlights include the company’s ongoing search for prospective office and research lab space on the campus of … Continue reading “NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Issues Corporate Update Detailing Q1 2018 Milestones”
Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP), alongside research arm Cannevert Therapeutics Ltd., this morning announced that it is in the process of obtaining a fairness opinion from Davidson & Company LLP of Vancouver, Canada, regarding Veritas’ planned acquisition of the remaining 20 percent of Cannevert in … Continue reading “NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Preparing for Planned Q1 Takeover of Cannevert Therapeutics”
Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning issued a follow-up statement to the memorandum issued by Attorney General Jeff Sessions on January 4, 2018, concerning marijuana enforcement and the repeal of the Cole Memo. In the update, Veritas noted that the AG’s decision largely relates … Continue reading “NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Responds to Cole Memo Repeal”
About Veritas Pharma Inc. Veritas Pharma Inc. is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas’ R&D arm, the company is clinically profiling various cannabis cultivars to pharmacologically connect unique strains with … Continue reading “NetworkNewsAudio – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) Interview”
Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning announced the addition of Dr. Brian O’Connor, a consultant in respiratory medicine, to its advisory board. Per the update, O’Connor is a clinical expert in the areas of asthma, chronic obstructive pulmonary disease (“COPD”), allergic disease and lung … Continue reading “NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Adds Dr. Brian O’Connor to Advisory Board”
Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning announced that it has completed a prestudy visit of the Fundación de Investigación (“FDI”) facilities in San Juan, Puerto Rico. Per the release, this will be the site where the company’s research arm, Cannevert Therapeutics Ltd. (“CTL”), will … Continue reading “NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Visits Clinical Trial Facility in San Juan, Puerto Rico”
Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning announced that Health Canada has issued its research and development subsidiary, Cannevert Therapeutics Ltd. (“CTL”), a dealer license allowing it to possess, analyze, sale, send, transport and deliver cannabis, hemp and related products. Per the release, reception of … Continue reading “NetworkNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Subsidiary Receives Dealer License from Health Canada”
